P2X7 receptor and macrophage function

被引:43
作者
Wewers, Mark D. [1 ,2 ]
Sarkar, Anasuya [2 ]
机构
[1] Ohio State Univ, Davis Heart & Lung Res Inst 201, Columbus, OH 43210 USA
[2] Ohio State Univ, Davis Heart & Lung Res Inst, Div Pulm Allergy Crit Care & Sleep Med, Columbus, OH 43210 USA
关键词
Macrophage; IL-18; LPS; Priming; AG126; Tyrosine kinase; ALVEOLAR MACROPHAGES; INTERLEUKIN-1-BETA RELEASE; MONONUCLEAR PHAGOCYTES; ANTIMICROBIAL ACTIVITY; IL-1-BETA RELEASE; HUMAN MONOCYTES; PORE FORMATION; HUMAN-LUNG; ATP; CASPASE-1;
D O I
10.1007/s11302-009-9131-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Macrophages are unique innate immune cells that play an integral role in the defense of the host by virtue of their ability to recognize, engulf, and kill pathogens while sending out danger signals via cytokines to recruit and activate inflammatory cells. It is becoming increasingly clear that purinergic signaling events are essential components of the macrophage response to pathogen challenges and disorders such as sepsis may be, at least in part, regulated by these important sensors. The activation of the P2X(7) receptor is a powerful event in the regulation of the caspase-1 inflammasome. We provide evidence that the inflammasome activation requires "priming" of macrophages prior to ATP activation of the P2X(7)R. Inhibition of the inflammasome activation by the tyrosine kinase inhibitor, AG126, suggests regulation by phosphorylation. Finally, the P2X(7)R may also be activated by other elements of the host response such as the antimicrobial peptide LL-37, which adds a new, physiologically relevant agonist to the P2X(7)R pathway. Therapeutic approaches to inflammation and sepsis will certainly be enhanced by an increased understanding of how purinergic receptors modulate the inflammasomes.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 42 条
[1]  
Aga M, 2002, J LEUKOCYTE BIOL, V72, P222
[2]  
AYALA JM, 1994, J IMMUNOL, V153, P2592
[3]   The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface [J].
Bals, R ;
Wang, XR ;
Zasloff, M ;
Wilson, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9541-9546
[4]   Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase [J].
Beigi, R ;
Kobatake, E ;
Aizawa, M ;
Dubyak, GR .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1999, 276 (01) :C267-C278
[5]   Blockade of human P2X7 receptor function with a monoclonal antibody [J].
Buell, G ;
Chessell, IP ;
Michel, AD ;
Colo, G ;
Salazzo, M ;
Herren, S ;
Gretener, D ;
Grahames, C ;
Kaur, R ;
Kosco-Vilbois, MH ;
Humphrey, PPA .
BLOOD, 1998, 92 (10) :3521-3528
[6]  
CRAPO JD, 1982, AM REV RESPIR DIS, V126, P332
[7]   The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation [J].
Cuzzocrea, S ;
McDonald, MC ;
Mazzon, E ;
Siriwardena, D ;
Calabrò, G ;
Britti, D ;
Mazzullo, G ;
De Sarro, A ;
Caputi, AP ;
Thiemermann, C .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (01) :145-158
[8]   A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1β processing and release [J].
Elssner, A ;
Duncan, M ;
Gavrilin, M ;
Wewers, MD .
JOURNAL OF IMMUNOLOGY, 2004, 172 (08) :4987-4994
[9]   Pulmonary defense and the human cathelicidin hCAP-18/LL-37 [J].
Fahy, RJ ;
Wewers, MA .
IMMUNOLOGIC RESEARCH, 2005, 31 (02) :75-89
[10]  
Fahy RJ, 1999, J IMMUNOL, V163, P1755